Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

Evaluating the Effect of Chronic Antihypertensive Therapy on New Onset Atrial Fibrillation and Clinical Outcomes in Septic Shock

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02876341

Enrollment

133

Registered

2016-08-23

Start date

2016-08-31

Completion date

2017-03-31

Last updated

2017-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Septic Shock

Keywords

Chronic antihypertensives, New onset atrial fibrillation, Septic shock

Brief summary

Retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock.

Detailed description

This will be a retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock. The two cohorts will be septic shock patients that were: 1) not on either a chronic β-blocker or angiotensin-converting-enzyme inhibitor (ACE inhibitor) or 2) on a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients 18 years of age or older * Diagnosis of septic shock requiring vasopressor therapy (norepinephrine, epinephrine, phenylephrine, dopamine, or vasopressin) * Admitted to the medical intensive care unit (MICU) at Rush University Medical Center (RUMC) * Time frame: 01/01/2012 to 07/1/2016

Exclusion criteria

* Pregnant patients * Transfer from outside hospital on vasopressors * Admitted to MICU in cardiopulmonary arrest * Prior arrest within 24 hours of admission to RUMC

Design outcomes

Primary

Measure	Time frame	Description
Cumulative percent (%) of patients with new onset atrial fibrillation at 48 hours	48 hours	New onset atrial fibrillation defined as atrial fibrillation not present on admission to MICU

Secondary

Measure	Time frame	Description
New onset of other arrhythmias	48 hours	Total onset of other arrhythmias not present on admission. Examples include, ventricular fibrillation, ventricular tachycardia, heart blocks, etc
Peak lactate	48 hours	Peak lactate level during the first 48 hours of admission
Duration of mechanical ventilation	During admission	—
In hospital mortality	During admission	—
Heart rate > 100	48 hours	Total number of times with heart rate greater than 100 in 48 hours.
90 day mortality	90 days after discharge	—
New onset atrial fibrillation for patients on other antiarrhythmics	24 and 48 hours	Antiarrhythmic agents that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. Will include any single or combination of class I, II, III, IV antiarrhythmic agents
Cumulative percent (%) of patients with new onset atrial fibrillation at 24 hours	24 hours	—
28 day mortality	28 days after discharge	—

Countries

United States

Outcome results